Royalty Pharma Management

Management criteria checks 3/4

Royalty Pharma's CEO is Pablo Legorreta, appointed in Jan 1996, has a tenure of 28.83 years. directly owns 0.83% of the company’s shares, worth $126.52M. The average tenure of the management team and the board of directors is 2.1 years and 4.4 years respectively.

Key information

Pablo Legorreta

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure28.8yrs
CEO ownership0.8%
Management average tenure2.1yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Nov 13
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma: Massive Opportunity Ahead

Nov 09

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Oct 14
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Oct 09
Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Aug 28
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Aug 22

Royalty Pharma: Busy Putting Capital To Work

Aug 11

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Jul 22
Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25
Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22
Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26
Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

CEO Compensation Analysis

How has Pablo Legorreta's remuneration changed compared to Royalty Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$1b

Jun 30 2024n/an/a

US$673m

Mar 31 2024n/an/a

US$799m

Dec 31 2023n/an/a

US$1b

Sep 30 2023n/an/a

US$184m

Jun 30 2023n/an/a

US$255m

Mar 31 2023n/an/a

US$332m

Dec 31 2022n/an/a

US$43m

Sep 30 2022n/an/a

US$507m

Jun 30 2022n/an/a

US$466m

Mar 31 2022n/an/a

US$602m

Dec 31 2021US$50mUS$8m

US$620m

Sep 30 2021n/an/a

US$783m

Jun 30 2021n/an/a

US$972m

Mar 31 2021n/an/a

US$493m

Dec 31 2020US$56mn/a

US$495m

Sep 30 2020n/an/a

US$2b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$29mn/a

US$2b

Compensation vs Market: Insufficient data to establish whether Pablo's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Pablo's compensation has been consistent with company performance over the past year.


CEO

Pablo Legorreta (60 yo)

28.8yrs

Tenure

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...


Leadership Team

NamePositionTenureCompensationOwnership
Pablo Legorreta
Founder28.8yrsno data0.83%
$ 126.5m
Terrance Coyne
Executive VP & CFOno dataUS$4.56m0.19%
$ 29.0m
George Lloyd
Executive VP of Investments & Chief Legal Officer2.1yrsUS$4.56m0.24%
$ 37.1m
Christopher Hite
Vice Chairman & Executive VP4.6yrsUS$4.56m0.083%
$ 12.8m
Marshall Urist
Executive Vice President of Research & Investments3.9yrsUS$4.56m0.015%
$ 2.3m
Arthur McGivern
Executive Vice President of Investments & General Counsel2.1yrsno datano data
Ashwin Pai
Executive Vice President of Investments1.6yrsno datano data
Kristin Stafford
Senior VP & Chief Accounting Officerno datano datano data
Eric Schneider
Senior VP & Chief Technology Officer1.2yrsno datano data
James Reddoch
Executive VP of Investments & Chief Scientific Officer3.9yrsUS$3.40mno data
George Grofik
Senior VP and Head of Investor Relations & Communicationsno datano datano data
Molly Sawaya
Executive VP & Head of Human Capitalless than a yearno datano data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: RPRX's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pablo Legorreta
Founder28.8yrsno data0.83%
$ 126.5m
David Hodgson
Independent Director2.4yrsUS$389.77k0.0037%
$ 567.0k
Ted Love
Independent Director4.3yrsUS$389.77k0.0083%
$ 1.3m
Errol De Souza
Independent Director4.4yrsUS$389.77k0.015%
$ 2.2m
Henry Fernandez
Lead Independent Director4.3yrsUS$389.77k0.023%
$ 3.5m
Gregory Norden
Independent Director4.4yrsUS$389.77k0.015%
$ 2.2m
Bonnie Bassler
Independent Director4.4yrsUS$389.77k0.011%
$ 1.7m
Catherine Engelbert
Independent Director4.4yrsUS$389.77k0.0077%
$ 1.2m

4.4yrs

Average Tenure

65.5yo

Average Age

Experienced Board: RPRX's board of directors are considered experienced (4.4 years average tenure).